Elevai Labs (ELAB) Competitors $2.56 +0.21 (+8.94%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ELAB vs. IBIO, PULM, NNVC, INAB, COCP, BFRG, TENX, CTXR, CGTX, and FNCHShould you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include iBio (IBIO), Pulmatrix (PULM), NanoViricides (NNVC), IN8bio (INAB), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), Tenax Therapeutics (TENX), Citius Pharmaceuticals (CTXR), Cognition Therapeutics (CGTX), and Finch Therapeutics Group (FNCH). These companies are all part of the "pharmaceutical products" industry. Elevai Labs vs. iBio Pulmatrix NanoViricides IN8bio Cocrystal Pharma Bullfrog AI Tenax Therapeutics Citius Pharmaceuticals Cognition Therapeutics Finch Therapeutics Group Elevai Labs (NASDAQ:ELAB) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, community ranking, valuation, institutional ownership, media sentiment, profitability and dividends. Does the MarketBeat Community favor ELAB or IBIO? iBio received 3 more outperform votes than Elevai Labs when rated by MarketBeat users. CompanyUnderperformOutperformElevai LabsN/AN/AiBioOutperform Votes342.86% Underperform Votes457.14% Which has stronger valuation & earnings, ELAB or IBIO? Elevai Labs has higher revenue and earnings than iBio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElevai Labs$2.45M2.71-$4.30M-$62.00-0.04iBio$175K129.65-$24.91MN/AN/A Do analysts prefer ELAB or IBIO? iBio has a consensus target price of $4.30, indicating a potential upside of 73.39%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Elevai Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elevai Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00iBio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of ELAB or IBIO? 22.2% of Elevai Labs shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 1.3% of Elevai Labs shares are held by insiders. Comparatively, 0.6% of iBio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ELAB or IBIO more profitable? iBio has a net margin of 0.00% compared to Elevai Labs' net margin of -223.41%. iBio's return on equity of -78.53% beat Elevai Labs' return on equity.Company Net Margins Return on Equity Return on Assets Elevai Labs-223.41% -124.93% -85.10% iBio N/A -78.53%-41.79% Does the media refer more to ELAB or IBIO? In the previous week, Elevai Labs had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Elevai Labs and 2 mentions for iBio. Elevai Labs' average media sentiment score of 0.00 equaled iBio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elevai Labs 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryiBio beats Elevai Labs on 8 of the 13 factors compared between the two stocks. Ad Weiss RatingsBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. Get Elevai Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELAB vs. The Competition Export to ExcelMetricElevai LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.63M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.0410.5991.3417.19Price / Sales2.71195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book0.065.104.794.78Net Income-$4.30M$151.51M$120.07M$225.60M7 Day Performance11.79%-2.14%-1.90%-1.24%1 Month Performance-36.63%-3.13%11.43%3.06%1 Year Performance-99.30%11.51%30.59%16.50% Elevai Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELABElevai Labs0.3443 of 5 stars$2.56+8.9%N/A-99.3%$6.63M$2.45M-0.0418News CoverageGap DownHigh Trading VolumeIBIOiBio0.988 of 5 stars$2.35+1.7%$4.30+83.0%N/A$21.50M$175,000.000.00100PULMPulmatrix0.1934 of 5 stars$5.88+2.3%N/A+209.2%$21.46M$7.30M-2.1820Analyst ForecastNews CoverageNNVCNanoViricidesN/A$1.49+0.7%N/A+36.7%$20.78MN/A-1.9520INABIN8bio3.6456 of 5 stars$0.28-0.3%$7.75+2,628.9%-82.2%$20.59MN/A-0.3820Gap DownCOCPCocrystal Pharma2.6621 of 5 stars$2.00+4.8%$7.00+250.0%+21.6%$20.35MN/A-1.0310Positive NewsBFRGBullfrog AI0.7327 of 5 stars$2.32+4.5%N/A-27.6%$20.21M$60,000.00-2.744News CoverageTENXTenax Therapeutics1.4636 of 5 stars$5.80-1.4%$16.00+175.9%-76.7%$19.78MN/A0.009News CoverageCTXRCitius Pharmaceuticals1.6657 of 5 stars$2.70-3.2%$100.00+3,603.7%-86.8%$19.52MN/A-0.4720Gap DownCGTXCognition Therapeutics2.9027 of 5 stars$0.46-4.5%$8.00+1,652.8%-62.3%$18.96MN/A-0.4920Analyst ForecastNews CoverageFNCHFinch Therapeutics GroupN/A$11.75-2.1%N/A+264.2%$18.87M$110,000.00-1.36190News Coverage Related Companies and Tools Related Companies IBIO Alternatives PULM Alternatives NNVC Alternatives INAB Alternatives COCP Alternatives BFRG Alternatives TENX Alternatives CTXR Alternatives CGTX Alternatives FNCH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELAB) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevai Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevai Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
